title: Decreased number of mast cells infiltrating into needle biopsy specimens leads to a better prognosis of prostate cancer.
abstract: Mast cell infiltration is often observed around human tumours. Inflammatory cells such as macrophages, neutrophils and mast cells infiltrating around tumours are known to contribute to tumour growth; however, the clinical significance of mast cell invasion in prostate cancer (PCa) has not been investigated. Mast cell infiltration was evaluated in 104 patients (age range, 45-88 years; median, 72 years), who underwent needle biopsy of the prostate and were confirmed to have PCa. Needle biopsy specimens of prostate were sliced into 5-microm-thick sections and immunostained for mast cells with monoclonal antibody against mast cell-specific tryptase. Mast cells were counted systematically under a microscope (x 400 magnification), and the relations between mast cell numbers and clinicopathologic findings were evaluated. The mast cell count was evaluated for prognostic value by multivariate analysis. Mast cells were immunostained around the cancer foci. The median number of mast cells in each case was 16. The mast cell count was higher around cancer foci in patients with higher Gleason scores than in those with low Gleason scores. The mast cell number correlated well with clinical stage (P<0.001). Prostate-specific antigen-free survival of patients with higher mast cell counts was better than that in patients with lower mast cell counts (P<0.001). Multivariate analysis revealed that mast cell count was a significant prognostic factor (P<0.005). The number of mast cells infiltrating around cancer foci in prostate biopsy specimens can be a significant prognostic factor of PCa.
authors.affiliation: Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan. nono@uro.med.osaka-u.ac.jp
authors.forename: N
authors.initials: N
authors.lastname: Nonomura
authors.forename: H
authors.initials: H
authors.lastname: Takayama
authors.forename: K
authors.initials: K
authors.lastname: Nishimura
authors.forename: D
authors.initials: D
authors.lastname: Oka
authors.forename: Y
authors.initials: Y
authors.lastname: Nakai
authors.forename: M
authors.initials: M
authors.lastname: Shiba
authors.forename: A
authors.initials: A
authors.lastname: Tsujimura
authors.forename: M
authors.initials: M
authors.lastname: Nakayama
authors.forename: K
authors.initials: K
authors.lastname: Aozasa
authors.forename: A
authors.initials: A
authors.lastname: Okuyama
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001707:Biopsy, Needle; D006801:Humans; D008297:Male; D008407:Mast Cells / Q000276:immunology / Q000473:pathology*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000473:pathology / Q000628:therapy; D009367:Neoplasm Staging; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000276:immunology / Q000473:pathology* / Q000628:therapy; D015996:Survival Rate